Abstract
Several studies suggest that Cr(Pic)3 confers anti‐inflammatory effects while others have reported a clastogenic effect. Utilizing the severely insulin resistant obese Zucker rats, we tested the hypothesis that chronic Cr(Pic)3 treatment improves glycemic control in association with reductions in markers of oxidative DNA damage (i.e., urinary 8‐hydroxy deoxyguanosine (8‐OHdG)) and inflammation (i.e., urinary monocyte chemoattractant protein‐1 (MCP‐1)). Accordingly, obese Zucker rats were treated with a diet containing 10 mg/kg chromium (as Cr(Pic)3) from 6 weeks to 6 months of age; untreated lean and obese Zucker rats served as controls. The treatment did not improve the glycemic status of obese Zucker rats as indexed by blood glucose, plasma insulin or hemoglobin A1c levels. Similarly, urinary MCP‐1 was not affected by excess dietary intake of Cr(Pic)3. Interestingly, urinary 8‐OHdG excretion was reduced in the treated than untreated obese Zucker rats (p<0.05). However, neither mean arterial pressure nor other indices of renal function (e.g., proteinuria, creatinine clearance or urine osmolality) were affected by chronic treatment with Cr(Pic)3. Taken together, the results suggest that dietary supplementation with Cr(Pic)3 decreases oxidative DNA damage in obese Zucker rats that is not accompanied by changes on blood pressure or glycemic status of the animal. Supported by NIH.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
